![](https://orsprogram.org/wp-content/uploads/2024/07/AdobeStock_291558089-scaled.jpg)
CBS News Reports on NJ Department of Health Tianeptine Health Alert
The emergence of tianeptine, a prescription drug used for depression but not approved for use in the U.S. and labeled
The Overdose Response Strategy (ORS) is an unprecedented and unique public health-public safety partnership between the Office of National Drug Control Policy (ONDCP) and the U.S. Centers for Disease Control and Prevention (CDC) through their support of the High Intensity Drug Trafficking Areas (HIDTA) program and CDC Foundation. At its core, the ORS is an example of a cross-agency, interdisciplinary collaboration with a single mission of reducing overdose deaths and saving lives across the United States.
The ORS, a partnership between CDC and ONDCP, with support from HIDTA and the CDC Foundation, has grown tremendously since its inception. The program began in 2015 with only five originating HIDTAs, covering 15 states. Today, the program includes all 33 HIDTAs, covering 50 states, Puerto Rico and the U.S. Virgin Islands.
…the importance of public health and safety partnerships like the Overdose Response Strategy [is] to help us meet people where they are in order to save lives…
WHAT WE DO
Each year, the ORS conducts an initiative-wide Cornerstone Project. These projects mobilize the entire ORS network to answer common questions or address shared informational needs that affect the ORS region as a whole.
The emergence of tianeptine, a prescription drug used for depression but not approved for use in the U.S. and labeled
The New York Overdose Response Strategy (ORS) team collaborated with the 13 public forensic labs that analyze seized drugs and
Identifying a champion or strategy to advocate for Overdose Detection Mapping Application (ODMAP) utilization among stakeholders can be valuable for
The Connecticut ORS team, with the U.S. Attorney’s Office, initiated a project to address the educational gap in substance use